For research use only
| Cat No. | ABC-X0032C |
| Product Type | Overexpression Stable Cell Lines |
| Cell Type | Lymphocyte |
| Species | Human |
| Host Cell | BAF3 |
| Source Organ | Lymphatic |
| Disease | Normal |
| Storage | Liquid Nitrogen |
The FLT3 (ITD_N701K) BAF3 cell line provides a robust model for studying hematologic malignancies, evaluating the resistance mechanisms of FLT.
Human FLT3 (ITD_N701K) BAF3 Cell Line is a genetically engineered model derived from selected murine Ba/F3 parental cell line based on customers’ requirement. FLT3 (ITD_N701K) BAF3 mutant cell line is generated by stable integration of exogenous human FLT3 gene harboring internal tandem duplication (ITD) and N701K mutation into Ba/F3 host cells using our optimized transduction of lentiviral vectors.
Target
FLT3 is a receptor tyrosine kinase involved in hematopoietic stem cell proliferation and survival. The ITD and N701K mutations result in ligand-independent dimerization and constitutive activation of FLT3 signaling, driving leukemogenesis. These mutations are frequently identified in acute myeloid leukemia (AML) and are associated with poor prognosis and therapy resistance. AcceGen offers generation of stable overexpression and multi-mutation models for targeted research applications. Polyclonal or monoclonal is optional based on customers’ research needs.
| Species | Human |
| Cat.No | ABC-X0032C |
| Product Category | Transfected Stable Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocyte |
| Growth Mode | Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 °C, 5% CO₂ |
| Source Organ | Lymphatic |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Overexpression Stable Cell Lines |
| Host Cell | BAF3 |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
The FLT3 (ITD_N701K) BAF3 Cell Line serves as a powerful model to investigate dual-mutant FLT3 signaling in hematologic malignancies. This platform enables evaluation of FLT3 inhibitor efficacy, resistance mechanisms, and pathway-specific combination treatments in preclinical drug discovery settings.